Current strategies in the treatment of Parkinson’s disease and a personalized approach to management

References

• de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol.5, 525–535 (2006).
   PubMed Web of Science ®Google Scholar
• Lilienfeld DE, Perl DP. Projected neurodegeneration disease mortality in the United States, 1990–2040. Neuroepidemiology12, 219–228 (1993).
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med.321, 1364–1371 (1989).
   PubMed Web of Science ®Google Scholar
• Giladi N, McDermont MP, Fahn S et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology56, 1712–1721 (2001).
   PubMed Web of Science ®Google Scholar
• Miyasaki HM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson’s disease (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology58, 11–17 (2002).
   PubMed Web of Science ®Google Scholar
• Clarke A, Johnson ES, Mallard N et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J. Neural Transm.110, 1257–1271 (2003).
   PubMed Web of Science ®Google Scholar
• Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline study group. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord.19, 426–432 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed start study of rasagiline in early Parkinson disease: the TEMPO study. Arch. Neurol.59, 1937–1943 (2004).
   Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed start study of rasagiline in early Parkinson disease. Arch. Neurol.61, 561–566 (2004).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Lewy MF, Howard I et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov. Disord.24(4), 564–573 (2008).
   Google Scholar
• Olanow CW, Hauser RA, Jankovic J et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (the ADAGIO study): Rationale, design, and baseline characteristics. Mov. Disord.23(15), 2194–2201 (2008).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med.361(13), 1268–1278 (2009).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations (the PRESTO study). Arch. Neurol.62, 241–248 (2005).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brook DJ, Melamed E et al.; LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting Effect in Adjunctive Therapy with Rasagiline Given Once Daily, study): a randomised, double-blind, parallel. Lancet365, 947–954 (2005).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized, controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD study. Clin. Neuropharmacol.23(1), 34–44 (2000).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease. Arch. Neurol.66(5), 563–570 (2009).
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Head J, Schrag A, Ben-Shlmo Y, Lees AJ. Parkinson’s Disease Research Group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing initial treatments in PD. Neurology71, 474–480 (2008).
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems predominate at 15 years. Mov. Disord.20, 190–199 (2005).
   PubMed Web of Science ®Google Scholar
• Weiner WJ, Reich SG. Agonist or levodopa for Parkinson disease?: ultimately, it doesn’t matter; neither is good enough. Neurology71(7), 470–471 (2008).
   PubMedGoogle Scholar
• Pahwa R, Stacy MA, Factor SA et al. Ropinirole 24 hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology68, 1108–1115 (2007).
   PubMed Web of Science ®Google Scholar
• Nashatizadeh MM, Lyons KE, Pahwa R. A review of ropinirole prolonged release in Parkinson’s disease. Clin. Interv. Aging4, 179–186 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas A, Iacono D, Luciano AL, Armellio K, Di Iorio A, Onofrj M. Duration of amantadine benefit in dyskinesia of severe Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry75, 141–143 (2004).
   PubMed Web of Science ®Google Scholar
• Fabrizio S, Tagliati M, Olanow CW. Treatment of levodopa induced motor complications. Mov. Disord.23(3), S599–S612 (2008).
   PubMedGoogle Scholar
• Waters CH. Diagnosis and Management of Parkinson’s Disease. Professional Communications Inc., OK, USA 154–155, 195–196, 201 (2006).
   Google Scholar
• Fahn S, Oakes D, Shoulson I et al. Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med.351, 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Myllyla VV, Kultalahi ER, Haapaniemi H, Leinonen. FILOMEN Study Group. Twelve month safety study of entacapone in patient’s with Parkinson’s disease. Eur. J. Neurol.8, 53–60 (2001).
   PubMed Web of Science ®Google Scholar
• Bass H, Beiske AG, Ghika J et al. Catechol-O-methyltransferase inhibition reduces the ‘wearing off’ phenomenon and levodopa requirements in fluctuating parkinsonian patients. J. Neurol. Neurosurg. Psychiatry63, 421–428 (1997).
   PubMedGoogle Scholar
• Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology51, 1309–1314 (1998).
   PubMed Web of Science ®Google Scholar
• The NINDS NET-PD Investigators. A randomized, double-blind, futility, clinical trial of creatine and minocycline in early Parkinson’s disease. Neurology66, 664–671 (2006).
   PubMed Web of Science ®Google Scholar
• The NINDS NET-PD Investigators. A randomized, clinical trial of coenzyme Q10 and GPI-1485 in early Parkisnon’s disease. Neurology68, 20–28 (2007).
   PubMed Web of Science ®Google Scholar
• Devos D; for the French DUODOPA Study Group. Patient profile, indications, efficacy, and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov. Disord.24(7), 993–1000 (2009).
   PubMed Web of Science ®Google Scholar
• Holger H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects of nonmotor symptoms and quality of life. Mov. Disord.24(10), 1468–1474 (2009).
   PubMedGoogle Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa related dyskinesia and motor complications as estimated from the cumulative literature. Mov. Disord.16, 448–458 (2001).
   PubMed Web of Science ®Google Scholar
• Silver GA, Voung K, Jankovic J. Young-onset versus late-onset Parkinson’s disease: clinical features and disease progression. Mov. Disord.19(Suppl. 9), S264 (2004).
   Google Scholar
• Waters CH. Managing the late complications of Parkinson’s disease. Neurology49(1), S49–S57 (1997).
   PubMedGoogle Scholar
• Pahwa R, Factor S, Lyons KE et al. Quality Standards Subcommittee of the American Academy of Neurology Practice Parameter: treatment of Parkinson’s disease with motor fluctuations and dyskinesia (an evidence based review) report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66, 983–995 (2006).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov. Disord.20, S11–S16 (2005).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov. Disord.20(5), 523–539 (2005).
   PubMed Web of Science ®Google Scholar
• Durif F, Vidailhet M, Assal F, Poche C, Bonnet AM, Agid Y. Low dose clozapine improves dyskinesias in Parkinson’s disease. Neurology48, 658–662 (1997).
   PubMed Web of Science ®Google Scholar
• Durif F, Debilly B, Galitzky M et al. Clozapine improves dyskinesias in Parkinson’s disease: a double blind placebo controlled study. Neurology62, 381–388 (2004).
   PubMed Web of Science ®Google Scholar
• Giladi N. Medical treatment of freezing of gait. Mov. Disord.23(Suppl. 2), S482–S488 (2008).
   PubMed Web of Science ®Google Scholar
• Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease: drug-induced psychiatric states. Adv. Neurol.65, 115–138 (1995).
   PubMedGoogle Scholar
• Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology, and risk factors. Brain123, 733–745 (2000).
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations in Parkinson’s disease. Neurol. Sci.23, 41–43 (2002).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric, and motor response to galantamine in Parkinson’s disease with dementia. Int. J. Geriatr. Psychiatry18, 937–941 (2003).
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Low dose clozapine for the treatment of drug induced psychosis in Parkinson’s disease. N. Engl. J. Med.340, 757–763 (1999).
   PubMed Web of Science ®Google Scholar
• Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease. Drugs Aging25(8), 665–682 (2008).
   PubMed Web of Science ®Google Scholar
• Mancini D, Zangaglia R, Cristina S et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov. Disord.18, 685–688 (2003).
   PubMedGoogle Scholar
• Ondo WG, Hunter C, Moore W. A double-blind, placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology62, 37–40 (2004).
   PubMed Web of Science ®Google Scholar
• Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson’s disease. Mov. Disord.13, 895–899 (1998).
   PubMed Web of Science ®Google Scholar
• Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson’s disease. Clin Cornerstone6, S12–S20 (2005).
   Google Scholar
• Rodriguez RL, Fernandez HH, Haq I, Okun MS. Pearls in patient selection in deep brain stimulation therapy. Neurologist13, 253–260 (2007).
   PubMed Web of Science ®Google Scholar
• Ferraye MU, Debu B, Pollak P. Deep brain stimulation effect on freezing of gait. Mov. Disord.23, S489–S494 (2008).
   PubMedGoogle Scholar
• Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA301(1), 63–73 (2009).
   PubMed Web of Science ®Google Scholar